Our Platform
Restoring balance to the immune system
We are pioneering thymus-targeted, bifunctional antibodies designed to restore balance to the immune system and address a broad range of autoimmune diseases. Achieving central immune tolerance has long been a major therapeutic goal, offering the potential for long-lasting, disease-modifying therapies for autoimmune diseases without the limitations of conventional immunosuppressive therapies and emerging approaches.
Designed to deliver a targeted and durable effect
Our foundational insights into thymic biology have led to the development of the first systemically administered therapeutics designed to deliver self-antigens directly to thymic antigen-presenting cells (APCs). This approach promotes the development of tolerogenic regulatory T cells (Tregs) and the elimination of autoreactive conventional T cells. Our antibodies are specifically engineered for efficient thymic targeting, precise antigen presentation, and robust therapeutic activity.
Thymus-targeting element consists of a unique antibody variable domain that targets thymic antigen-presenting cells
Engineered Fc region optimizes the therapeutic effect of the bifunctional antibody
Peripheral antigen is recombinantly fused to antibody scaffold for delivery to the thymus to induce central tolerance
Zag Bio seeks to set a new standard for the treatment of autoimmune diseases
Targeted
Zag-induced thymic Tregs home to the site of inflammation, avoiding side effects of broad immunosuppression.
Durable
Thymus-derived Treg populations are exceptionally long-lived, enabling extended protection without the need for chronic treatment.
Amplified
Thymus-derived Tregs promote bystander suppression, deepening response and expanding possible disease applications.
Flexible
Modular antibody approach enables expansion to a diverse set of diseases with scalable and reliable manufacturing.
